At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 6:38:03 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,040,100.00
3,819,000.00
17,310,600.00
18,976,700.00
482,300.00
Cost of Revenue
476,900.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
Gross Profit
2,563,200.00
3,219,200.00
14,315,600.00
16,065,200.00
423,000.00
Operating Expense
3,286,100.00
2,315,000.00
2,011,800.00
1,138,100.00
505,400.00
Operating Income
-722,900.00
904,200.00
12,303,800.00
14,927,100.00
-82,400.00
Net Non Operating Interest Income Expense
475,000.00
349,700.00
29,600.00
-25,800.00
-3,500.00
Other Income Expense
--
-67,800.00
620,700.00
145,100.00
-59,900.00
Pretax Income
-315,700.00
1,186,100.00
12,954,100.00
15,046,400.00
-145,800.00
Tax Provision
151,200.00
255,800.00
3,519,700.00
4,753,900.00
-161,000.00
Net Income Common Stockholders
-466,900.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Diluted NI Available to Com Stockholders
-466,900.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Basic EPS
-1.92
3.87
38.78
42.18
0.06
Diluted EPS
-1.94
3.83
37.77
39.63
0.06
Basic Average Shares
240,931.30
240,600.00
243,280.04
244,000.00
253,300.00
Diluted Average Shares
241,167.74
242,700.00
249,785.54
259,700.00
253,300.00
Total Operating Income as Reported
-936,700.00
690,400.00
12,642,700.00
15,283,800.00
-82,400.00
Rent Expense Supplemental
--
--
--
--
2,390.00
Total Expenses
3,763,000.00
2,914,800.00
5,006,800.00
4,049,600.00
564,700.00
Net Income from Continuing & Discontinued Operation
-466,900.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Normalized Income
-409,270.00
983,455.20
8,982,530.40
10,193,251.60
57,130.00
Interest Income
493,200.00
357,600.00
48,500.00
1,500.00
1,600.00
Interest Expense
--
--
16,200.00
5,400.00
2,000.00
Net Interest Income
475,000.00
349,700.00
29,600.00
-25,800.00
-3,500.00
EBIT
-587,300.00
904,200.00
12,303,800.00
14,927,100.00
-143,800.00
EBITDA
-375,900.00
1,087,600.00
12,427,100.00
15,002,300.00
-105,100.00
Reconciled Cost of Revenue
476,900.00
599,800.00
2,995,000.00
2,911,500.00
59,300.00
Reconciled Depreciation
211,400.00
183,400.00
123,300.00
75,200.00
38,700.00
Net Income from Continuing Operation Net Minority Interest
-466,900.00
930,300.00
9,434,400.00
10,292,500.00
15,200.00
Total Unusual Items Excluding Goodwill
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Total Unusual Items
-67,800.00
-67,800.00
620,700.00
145,100.00
-59,900.00
Normalized EBITDA
-308,100.00
1,155,400.00
11,806,400.00
14,857,200.00
-45,200.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-10,170.00
-14,644.80
168,830.40
45,851.60
-17,970.00
12/31/2020 - 10/10/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MRNA Moderna, Inc.
41.83
-2.31%
VRTX Vertex Pharmaceuticals Incorporated
463.73
-0.08%
NVAX Novavax, Inc.
9.11
+1.00%
CVAC CureVac N.V.
3.1600
-1.25%
REGN Regeneron Pharmaceuticals, Inc.
731.30
-1.31%
SMMT Summit Therapeutics Inc.
17.83
-0.22%
CRSP CRISPR Therapeutics AG
43.78
-3.57%
NTLA Intellia Therapeutics, Inc.
12.90
-4.87%
VKTX Viking Therapeutics, Inc.
47.03
-1.75%
GPCR Structure Therapeutics Inc.
31.25
-1.45%